Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B

Trial Profile

Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Entecavir (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HBRN IT Adult
  • Most Recent Events

    • 29 Jun 2018 Status changed to discontinued.
    • 29 Jun 2018 Status changed to discontinued.
    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top